文献速递儿科与产科急症心脑血管急症重症综合管理与镇静镇痛

儿童多系统炎症综合征出院后糖皮质激素使用与临床结局

Postdischarge Glucocorticoid Use and Clinical Outcomes of Multisystem Inflammatory Syndrome in Children.
PubMed 文献 · JAMA Netw Open · 2022-11-01
一句话结论MIS-C合并心血管功能障碍患儿出院后糖皮质激素常被延长使用,但短疗程(<3周)与≥3周的临床结局相似,出院后体重增加常见。

这项多中心回顾性队列研究纳入13家美国医院2020年5月15日至2021年5月31日收治的186例MIS-C患儿,均住院期间接受静脉注射免疫球蛋白且有心血管功能障碍(需血管升压药或左心室射血分数≤55%),随访3个月。出院时93.0%继续糖皮质激素治疗,中位出院剂量42 mg/d或1.1 mg/kg/d,门诊疗程中位23天;住院病情严重程度与出院后激素疗程无关。激素疗程<3周与≥3周者C反应蛋白和铁蛋白恢复正常时间相似,再入院7例(3.8%)且无心血管原因,高血糖14例(8.1%)。43%患儿出院后体重增加≥2 kg,住院期大剂量静脉及口服激素治疗与出院后体重增加相关(校正OR 6.91,95%CI 1.92-24.91)。作者认为需优化MIS-C出院后激素疗程。

要点

  • 186例MIS-C合并心血管功能障碍患儿中93.0%出院后继续糖皮质激素,门诊疗程中位23天(IQR 15-32天),住院病情严重程度与出院后疗程无关。
  • 激素疗程<3周与≥3周者C反应蛋白和铁蛋白恢复正常时间相似。
  • 再入院7例(3.8%),无1例因心血管功能障碍;高血糖14例(8.1%)。
  • 75例(43%)出院后体重增加≥2 kg(中位4.1 kg,IQR 3.0-6.0 kg),住院期大剂量静脉及口服激素治疗与体重增加相关(校正OR 6.91,95%CI 1.92-24.91)。
  • 出院时中位激素剂量42 mg/d(IQR 30-60 mg/d)或1.1 mg/kg/d(IQR 0.7-1.7 mg/kg/d)。

适用人群与场景

  • 年龄<21岁、2020年5月15日至2021年5月31日入住13家美国医院的MIS-C患儿,住院期间接受静脉注射免疫球蛋白且有心血管功能障碍(需血管升压药或左心室射血分数≤55%),并有完整3个月门诊随访数据。

研究设计与关键结果

  • 多中心回顾性队列研究,纳入186例MIS-C患儿,中位年龄10.4岁(IQR 6.7-14.2岁),男性107例(57.5%),黑人非西班牙裔60例(32.3%),西班牙裔或拉丁裔59例(31.7%)。
  • 重症比例高:入住ICU 163例(87.6%),使用血管升压药134例(72.0%),住院期接受糖皮质激素178例(95.7%)。
  • 出院时继续糖皮质激素173例(93.0%),中位出院剂量42 mg/d(IQR 30-60 mg/d)或1.1 mg/kg/d(IQR 0.7-1.7 mg/kg/d);门诊疗程中位23天(IQR 15-32天)。
  • 住院病情严重程度与出院后糖皮质激素疗程无关;激素疗程<3周与≥3周者C反应蛋白和铁蛋白恢复正常时间相似。
  • 再入院7例(3.8%),无心血管功能障碍原因;高血糖14例(8.1%)。
  • 出院后体重增加≥2 kg者75例(43%),中位增加4.1 kg(IQR 3.0-6.0 kg);住院期大剂量静脉及口服糖皮质激素治疗与出院后体重增加相关(校正OR 6.91,95%CI 1.92-24.91)。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,需要制定策略优化MIS-C患儿的出院后糖皮质激素疗程。
  • 本队列中出院后糖皮质激素常被延长使用,但短疗程(<3周)与≥3周者临床结局相似;出院后体重增加常见,再入院少见且无心血管原因。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Minimal data are available regarding the postdischarge treatment of multisystem inflammatory syndrome in children (MIS-C).

OBJECTIVES: To evaluate clinical characteristics associated with duration of postdischarge glucocorticoid use and assess postdischarge clinical course, laboratory test result trajectories, and adverse events in a multicenter cohort with MIS-C.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients with MIS-C hospitalized with severe illness and followed up for 3 months in an ambulatory setting. Patients younger than 21 years who were admitted between May 15, 2020, and May 31, 2021, at 13 US hospitals were included. Inclusion criteria were inpatient treatment comprising intravenous immunoglobulin, diagnosis of cardiovascular dysfunction (vasopressor requirement or left ventricular ejection fraction ≤55%), and availability of complete outpatient data for 3 months.

EXPOSURES: Glucocorticoid treatment.

MAIN OUTCOMES AND MEASURES: Main outcomes were patient characteristics associated with postdischarge glucocorticoid treatment, laboratory test result trajectories, and adverse events. Multivariable regression was used to evaluate factors associated with postdischarge weight gain (≥2 kg in 3 months) and hyperglycemia during illness.

RESULTS: Among 186 patients, the median age was 10.4 years (IQR, 6.7-14.2 years); most were male (107 [57.5%]), Black non-Hispanic (60 [32.3%]), and Hispanic or Latino (59 [31.7%]). Most children were critically ill (intensive care unit admission, 163 [87.6%]; vasopressor receipt, 134 [72.0%]) and received inpatient glucocorticoid treatment (178 [95.7%]). Most were discharged with continued glucocorticoid treatment (173 [93.0%]); median discharge dose was 42 mg/d (IQR, 30-60 mg/d) or 1.1 mg/kg/d (IQR, 0.7-1.7 mg/kg/d). Inpatient severity of illness was not associated with duration of postdischarge glucocorticoid treatment. Outpatient treatment duration varied (median, 23 days; IQR, 15-32 days). Time to normalization of C-reactive protein and ferritin levels was similar for glucocorticoid duration of less than 3 weeks vs 3 or more weeks. Readmission occurred in 7 patients (3.8%); none was for cardiovascular dysfunction. Hyperglycemia developed in 14 patients (8.1%). Seventy-five patients (43%) gained 2 kg or more after discharge (median 4.1 kg; IQR, 3.0-6.0 kg). Inpatient high-dose intravenous and oral glucocorticoid therapy was associated with postdischarge weight gain (adjusted odds ratio, 6.91; 95% CI, 1.92-24.91).

CONCLUSIONS AND RELEVANCE: In this multicenter cohort of patients with MIS-C and cardiovascular dysfunction, postdischarge glucocorticoid treatment was often prolonged, but clinical outcomes were similar in patients prescribed shorter courses. Outpatient weight gain was common. Readmission was infrequent, with none for cardiovascular dysfunction. These findings suggest that strategies are needed to optimize postdischarge glucocorticoid courses for patients with MIS-C.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Son MBF, Berbert L, Young C, et al. Postdischarge Glucocorticoid Use and Clinical Outcomes of Multisystem Inflammatory Syndrome in Children. JAMA Netw Open. 2022. PMID: 36367723. doi:10.1001/jamanetworkopen.2022.41622

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。